Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, January 23, 2018

Administration of two proteins shown to counteract neurodegeneration in Parkinson's disease

You may need this due to your risk of Parkinsons after stroke. Better file this away so you can remember this when you need it.

Parkinson’s Disease May Have Link to Stroke


Administration of two proteins shown to counteract neurodegeneration in Parkinson's disease

A combination therapy made up of two neurotrophic factors has been shown to reduce the degenerative effects of Parkinson’s disease, report researchers from the UPV/EHU-University of the Basque Country.

Credit: Tatiana Shepeleva/Shutterstock.com
The two factors; Vascular Endothelial Growth Factor (VEGF) and Glial Cell-derived Neurotrophic Factor (GDNF), are proteins that play an essential role in nerve cell function by inducing cell growth, plasticity and survival.
Parkinson’s is a motor neuron disorder characterised by a loss of dopaminergic neurons in the substantia nigra of the brain.
These nerve cells are found in the black substance of the brain, where they produce the neurotransmitter dopamine, a key modulator of involuntary movement.
Using an experimental model, the researchers reproduced the various stages of Parkinson’s disease and investigated the therapeutic effects of applying the two neurotrophic factors.
As reported in Molecular Neurobiology, VEGF and GDNF were delivered in microspheres or nanospheres made up of a biodegradable polymer called Poly Lactic-co-glycolic Acid, which enables the proteins to be released in a gradual and continuous manner. This combined administration meant the researchers could assess any synergistic effect the two factors may induce.
Dr Catalina Requejo and colleagues reported encouraging findings for both early and late stages of Parkinson’s disease. Delivery of the VEGF/GDNF combination significantly reduced the degeneration of dopaminergic neurons in the black substance of the brain, as well as triggering new cell formation and cellular differentiation.
To confirm this synergistic effect, the team administered a molecule known to inhibit the cell receptors to which VEGF and GDNF bind.
The consequences for the dopaminergic system were even worse, which supports the beneficial synergistic effects exerted by the VEFG and the GDNF in Parkinson's"
Dr Catalina Requejo, Neuroscientist at UPV/EHU-University of the Basque Country.
The study also showed that the most effective results were observed when nanospheres were used as the delivery mode during early-stage disease, providing further evidence of the importance of early diagnosis and the therapeutic potential nanotechnology has to offer.
"Nanotechnology could be a very useful tool when it comes to administering neurotrophic factors," adds Requejo.

No comments:

Post a Comment